Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
INDOCO REMEDIES ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
INDOCO REMEDIES Mar-23 |
ADCOCK INGRAM Jun-14 |
INDOCO REMEDIES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 423 | 320 | - | |
Low | Rs | 308 | 231 | - | |
Sales per share (Unadj.) | Rs | 181.1 | 95.3 | - | |
Earnings per share (Unadj.) | Rs | 15.4 | -24.0 | - | |
Cash flow per share (Unadj.) | Rs | 23.1 | -19.9 | - | |
Dividends per share (Unadj.) | Rs | 2.25 | 0 | - | |
Avg Dividend yield | % | 0.6 | 0 | - | |
Book value per share (Unadj.) | Rs | 111.5 | 74.8 | - | |
Shares outstanding (eoy) | m | 92.15 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.0 | 2.9 | 69.8% | |
Avg P/E ratio | x | 23.7 | -11.5 | -206.2% | |
P/CF ratio (eoy) | x | 15.8 | -13.9 | -114.2% | |
Price / Book Value ratio | x | 3.3 | 3.7 | 88.9% | |
Dividend payout | % | 14.6 | 0 | - | |
Avg Mkt Cap | Rs m | 33,683 | 46,551 | 72.4% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 3,226 | 2,922 | 110.4% | |
Avg. sales/employee | Rs Th | 0 | 3,747.7 | - | |
Avg. wages/employee | Rs Th | 0 | 680.6 | - | |
Avg. net profit/employee | Rs Th | 0 | -944.3 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 16,686 | 16,089 | 103.7% | |
Other income | Rs m | 24 | 113 | 21.2% | |
Total revenues | Rs m | 16,710 | 16,201 | 103.1% | |
Gross profit | Rs m | 2,860 | -2,788 | -102.6% | |
Depreciation | Rs m | 706 | 694 | 101.7% | |
Interest | Rs m | 250 | 436 | 57.4% | |
Profit before tax | Rs m | 1,928 | -3,806 | -50.7% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 505 | 238 | 212.5% | |
Profit after tax | Rs m | 1,423 | -4,054 | -35.1% | |
Gross profit margin | % | 17.1 | -17.3 | -98.9% | |
Effective tax rate | % | 26.2 | -6.2 | -419.5% | |
Net profit margin | % | 8.5 | -25.2 | -33.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 8,082 | 11,784 | 68.6% | |
Current liabilities | Rs m | 4,245 | 6,630 | 64.0% | |
Net working cap to sales | % | 23.0 | 32.0 | 71.8% | |
Current ratio | x | 1.9 | 1.8 | 107.1% | |
Inventory Days | Days | 25 | 111 | 22.6% | |
Debtors Days | Days | 768 | 124 | 619.4% | |
Net fixed assets | Rs m | 9,055 | 6,869 | 131.8% | |
Share capital | Rs m | 184 | 75 | 246.7% | |
Net worth | Rs m | 10,276 | 12,628 | 81.4% | |
Long term debt | Rs m | 1,435 | 4,438 | 32.3% | |
Total assets | Rs m | 17,137 | 23,855 | 71.8% | |
Interest coverage | x | 8.7 | -7.7 | -112.6% | |
Debt to equity ratio | x | 0.1 | 0.4 | 39.7% | |
Sales to assets ratio | x | 1.0 | 0.7 | 144.4% | |
Return on assets | % | 9.8 | -15.2 | -64.4% | |
Return on equity | % | 13.8 | -32.1 | -43.1% | |
Return on capital | % | 18.6 | -19.8 | -93.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,788 | 1,373 | 130.2% | |
From Investments | Rs m | -2,082 | -422 | 493.7% | |
From Financial Activity | Rs m | 228 | 4,028 | 5.7% | |
Net Cashflow | Rs m | -65 | 4,979 | -1.3% |
Compare INDOCO REMEDIES With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare INDOCO REMEDIES With: UNICK FIX-A-FORM AND PRINTERS ROOPA INDUSTRIES MANGALAM DRUGS SOLARA ACTIVE PHARMA SCIENCES ADESHWAR MEDITEX
Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.